Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — November 2023

Biotek-snakken — November 2023

Planlagt Fastgjort Låst Flyttet Biotek-snakken
161 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • A Offline
    A Offline
    Aps_invest
    wrote on sidst redigeret af
    #128

    The study achieved the primary end point as the adjusted treatment differences between the products were within the predefined equivalence margin.

    1 Reply Last reply
    0
    • U Offline
      U Offline
      Urban
      wrote on sidst redigeret af
      #129

      @exitnu: Ja, men...
      https://www.centerforbiosimilars.com/view/the-european-union-gains-another-ranibizumab-biosimilar

      1 Reply Last reply
      0
      • exitnuE Offline
        exitnuE Offline
        exitnu
        wrote on sidst redigeret af
        #130

        "Ja, men..." kan du evt. uddybe?

        1 Reply Last reply
        0
        • J Offline
          J Offline
          Jazzz
          wrote on sidst redigeret af
          #131

          Erfaringen tilsiger at læger er enormt konservative og at det tager lang tid, at komme ind med et alternativt produkt til en eksisterende.. på den anden side, - og det er jo casen i en julenøddeskal, bør der komme en udvikling, som hjælper billigere produkter i markedet. Ellers drukner staterne i healthcare. Nu er muligheden der, med similars. Hvis staterne ikke hjælper til, er der ingen der gider investere i det i fremtiden…

          1 Reply Last reply
          0
          • J Offline
            J Offline
            Jazzz
            wrote on sidst redigeret af
            #132

            Men man bliver jo tit skuffet.. se på den grønne omstilling.. der sker jo stort set ikke noget. Så stater er bare ikke særligt dygtige..eller kvikke.

            1 Reply Last reply
            0
            • J Offline
              J Offline
              Jazzz
              wrote on sidst redigeret af
              #133

              Mit bet er dog stadig, at det nok skal komme…

              1 Reply Last reply
              0
              • U Offline
                U Offline
                Urban
                wrote on sidst redigeret af
                #134

                @exitnu: Markedsføringstilladelsen blev udstedt af EU i 2022. Hvordan Xbrane in- og eksternt, har brugt den efterfølgende tid, skal jeg ikke gøre mig klog på. De kommende faktuelle salgstal bliver uden tvivl vigtige for kursudviklingen. Jeg ejer ikke selv aktien.

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #135

                  Godmorgen 🙂

                  1 Reply Last reply
                  0
                  • F Offline
                    F Offline
                    Fandel
                    wrote on sidst redigeret af
                    #136

                    Godmorgen...

                    1 Reply Last reply
                    0
                    • exitnuE Offline
                      exitnuE Offline
                      exitnu
                      wrote on sidst redigeret af
                      #137

                      God morgen 🙂

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        LP90
                        wrote on sidst redigeret af
                        #138

                        Godmorgen 🙂

                        1 Reply Last reply
                        0
                        • exitnuE Offline
                          exitnuE Offline
                          exitnu
                          wrote on sidst redigeret af
                          #139

                          Xbrane Biopharma releases Interim report for January – September 2023:

                          Link Preview Image
                          » Xbrane Biopharma releases Interim report for January – September 2023Xbrane Biopharma releases Interim report for January – September 2023 – Xbrane

                          favicon

                          (xbrane.com)

                          1 Reply Last reply
                          0
                          • A Offline
                            A Offline
                            Aps_invest
                            wrote on sidst redigeret af
                            #140

                            Tja, indtægterne stiger pænt, men det gør udgifterne så også 🙂 Vel fornuftigt nok at begrænse udgifterne, så de kan nå målet om at blive cash positive senest i Q1 2025. FIRST NINE MONTHS 2023*
                            • Revenue amounted to SEK 171.8 m (40.3).

                            1 Reply Last reply
                            0
                            • A Offline
                              A Offline
                              Aps_invest
                              wrote on sidst redigeret af
                              #141

                              Nogen der har tal på hvad de havde forventet af omsætning på nuværende tidspunkt?

                              1 Reply Last reply
                              0
                              • exitnuE Offline
                                exitnuE Offline
                                exitnu
                                wrote on sidst redigeret af
                                #142

                                Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome:

                                Link Preview Image
                                Calliditas Therapeutics AB

                                Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

                                favicon

                                Calliditas Therapeutics AB (www.calliditas.se)

                                1 Reply Last reply
                                0
                                • exitnuE Offline
                                  exitnuE Offline
                                  exitnu
                                  wrote on sidst redigeret af
                                  #143

                                  @Apsinvest - Xbrane Biopharma - RE: har E2023 Net Earnings: MSEK 192,4.

                                  1 Reply Last reply
                                  0
                                  • exitnuE Offline
                                    exitnuE Offline
                                    exitnu
                                    wrote on sidst redigeret af
                                    #144

                                    Altså for hele 2023 ...

                                    1 Reply Last reply
                                    0
                                    • exitnuE Offline
                                      exitnuE Offline
                                      exitnu
                                      wrote on sidst redigeret af
                                      #145

                                      Xbrane Biopharma Q3 2023: Slightly higher revenues and softer EBIT:

                                      Just a moment...

                                      favicon

                                      (www.redeye.se)

                                      1 Reply Last reply
                                      0
                                      • exitnuE Offline
                                        exitnuE Offline
                                        exitnu
                                        wrote on sidst redigeret af
                                        #146

                                        "Redeye see a Q3 report from Xbrane that came in slightly above estimates in terms of revenues, but was softer than we had forecasted on the EBIT level, the company left Q3 with SEK167.3m in cash and cash equivalents on the balance sheet."

                                        1 Reply Last reply
                                        0
                                        • A Offline
                                          A Offline
                                          Aps_invest
                                          wrote on sidst redigeret af
                                          #147

                                          Det ligner mere røvfuld idag 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper